Download DNB 2019 June MEDICAL ONCOLOGY MEDICAL ONCOLOGY PAPER 1 Question Paper

Download Diplomate in National Board (DNB) 2019 June MEDICAL ONCOLOGY MEDICAL ONCOLOGY PAPER 1 Previous Question Papers

FINAL EXAM
JUNE 2019
Time: 3 hours
NATIONAL BOARD OF EXAMINATIONS
MEDICAL ONCOLOGY
PAPER-l
Max. Marksz100
Important Instructions:
Attempt all questions in order.
Each question carries 10 marks.
Read the question carefully and answer to the point neatly and legib/y.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space.
Answer all the parts of a single question together.
Start the answer to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/f/owcharts wherever appropriate.
Write short notes on:
1 .
a)
b)
C)
a)
b)
C)
a)
b)
C)
a)
b)
C)
a)
b)
0)
Next generation sequencing (NGS).
Passenger & Driver mutations.
AIIeIe-Specific polymerase chain reaction
What are the constituent cell types of the tumour
microenvironment?
Dynamics and co-evolution of the tumour microenvironment
during the carcinogenesis.
Mention therapies targeting hall marks of the cancer.
Mechanisms of chemical carcinogenesis.
Microbiota & carcinogenesis.
Cancers caused by EBV.
Mechanism of radiation induced cellular damage.
Proton beam therapy.
Radiosensitizers in cancer therapy.
Immune checkpoints in a cell and their inhibitors in cancer
treatment.
Adverse effects of immune check point inhibitors and their
management.
Talimogene laherparepvec (T-VEC).
Indications of Genetic counseling in hereditary cancer
syndromes.
Components of Cancer Genetic counseling.
Role of surgery in cancer prevention.
Biochemistry of the ubiquitin proteasome pathway.
Proteasome inhibitors - mechanisms of action, indications
and side effects.
-1-
MED ONCO/J/19/17/I
4+3+3
3+3+4
4+4+2
4+3+3
4+4+2
3+3+4
4+6
P.T.O.
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.

FINAL EXAM
JUNE 2019
10.
a)
b)
0)
NATIONAL BOARD OF EXAMINATIONS
MEDICAL ONCOLOGY
PAPER-I
What is a tumour biomarker? 2+3+5
Potential uses of tumour biomarker tests.
What are the criteria to incorporate a tumour biomarker test
into clinical practice?
Anti HER-2 neu therapeutic agents in breast cancer. 4+3+3
Monitoring and management of cardiotoxicity of anti- HER 2
therapy.
Differences between anthracyclin induced and anti- HER-2
agents induced cardiotoxicity.
What is a biosimilar? 2+4+4
Criteria used in biosimilar approval process.
Advantages & disadvantages of use of biosimilar.
**************
-2-
POSSESSION/USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.